這是一項開放標籤、隨機、2臂、多中心、第三期研究，主要目標是比較brentuximab vedotin（ADCETRIS®）加上AVD（doxorubicin［Adriamycin］、vinblastine及dacarbazine；簡稱A+AVD）與ABVD（doxorubicin［Adriamycin］、bleomycin、vinblastine及dacarbazine）用於晚期典型何傑金氏淋巴瘤（HL）第一線治療所達到的修訂版無惡化存活期（mPFS）。
適應症：Hodgkin Lymphoma
收案條件
納入條件
- Treatment-naïve participants with Ann Arbor Stage III or IV HL.
- Histologically confirmed classical Hodgkin Lymphoma (HL) according to the current World Health Organization (WHO) classification.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\<=) 2.
- Bidimensional measurable disease as documented by radiographic technique per the International Working Group Revised Criteria for Response Assessment for Malignant Lymphoma.
排除條件
- Nodular lymphocyte predominant Hodgkin lymphoma.
- Cerebral/meningeal disease, including signs and symptoms of progressive multifocalleukoencephalopathy (PML).
- Sensory or motor peripheral neuropathy.
- Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 12 weeks of first study drug dose.
- Known human immunodeficiency virus (HIV) positive.
- Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。